Used in pharmaceutical research as a prodrug derivative to improve the bioavailability and targeted delivery of capecitabine, enhancing its efficacy in cancer treatment, particularly for solid tumors like colorectal and breast cancer. The cyclic carbonate modification increases lipophilicity, promoting better cellular uptake and controlled release of the active drug in tumor tissues. Investigated for potential use in advanced drug delivery systems, including nanoparticle-based therapies and sustained-release formulations.